ARCELLX, INC.

Profile

Company Names

ARCELLX, INC.

Addresses

25 WEST WATKINS MILL ROAD, SUITE A, GAITHERSBURG, MD 20878

20271 GOLDENROD LANE, SUITE 2099, GERMANTOWN, MD 20876

Phone Numbers

240-723-6641

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2014

State Incorporated:

DELAWARE

Total Amount Raised:

$272,840,625.00

Number of Funding Rounds:

4
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
4
2023-01-26 
$100,000,003.00 
$100,000,003.00 
$0.00 
Equity 
3
2022-02-27 
$9,999,986.00 
$9,999,986.00 
$0.00 
Equity 
2
2021-03-26 
$120,000,023.00 
$120,000,023.00 
$0.00 
Equity 
1
2019-08-09 
$42,840,613.00 
$83,681,224.00 
$40,840,611.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
TIBA 
 
AYNECHI 
DIRECTOR
THESAN PHARMACEUTICALS, INC.   |  IRHYTHM TECHNOLOGIES, INC.   |  ANAPTYSBIO INC   |  GENOA PHARMACEUTICALS, INC.   |  MIRUM PHARMACEUTICALS, INC.   |  ARCELLX, INC.   |  NKARTA, INC.   |  AVALYN PHARMA INC.   |  SPRUCE BIOSCIENCES, INC.   |  ARISTEA THERAPEUTICS, INC.   |  MBX BIOSCIENCES, INC.   |  REZO THERAPEUTICS, INC.   |  RAY THERAPEUTICS, INC.
HUGO 
 
BEEKMAN 
DIRECTOR
ARCELLX, INC.   |  EVOLVEIMMUNE THERAPEUTICS HOLDING COMPANY, LLC
ALI 
 
BEHBAHANI 
DIRECTOR
ROTATION MEDICAL INC   |  DENALI MEDICAL II, INC.   |  MINERVA SURGICAL INC   |  PROSPEX MEDICAL III, INC.   |  OCULEVE, INC.   |  CVRX INC   |  IVANTIS, INC.   |  ADAPTIMMUNE LTD   |  CARDIONOMIC, INC.   |  CVRX, INC.   |  SOLACE THERAPEUTICS INC   |  CRISPR THERAPEUTICS AG   |  OYSTER POINT PHARMA, INC.   |  GENOCEA BIOSCIENCES, INC.   |  BLACK DIAMOND THERAPEUTICS, INC.   |  SPYGLASS OPHTHALMICS, INC.   |  ARCELLX, INC.   |  NKARTA, INC.   |  NEA BH SPV, L.P.   |  NEA BH SPV II, L.P.   |  MONTE ROSA THERAPEUTICS, INC.   |  858 THERAPEUTICS, INC.   |  NEW ENTERPRISE ASSOCIATES 18, L.P.   |  NEA 18 VENTURE GROWTH EQUITY, L.P.   |  FIRSTLIGHT BIO, INC.   |  NEXO THERAPEUTICS, INC.   |  LAUNCHPAD THERAPEUTICS, INC.   |  NEA SH SPV, L.P.   |  SPYGLASSPHARMA, INC.   |  NEA RP SPV, L.P.   |  NEA CH SPV, L.P.   |  NEA TS 2024 SPV, L.P.   |  NEA SECONDARY OPPORTUNITY FUND, L.P.   |  TUNE THERAPEUTICS, INC.
JILL 
 
CARROLL 
DIRECTOR
VASCULOX, INC.   |  TIOMA THERAPEUTICS, INC.   |  ARCELLX, INC.   |  NKARTA, INC.   |  PANDION THERAPEUTICS HOLDCO LLC   |  ODYSSEY THERAPEUTICS, INC.   |  AVALYN PHARMA INC.   |  AIRNEXIS THERAPEUTICS, INC.
RAMI 
 
ELGHANDOUR 
EXECUTIVE OFFICER, DIRECTOR
OTHERA PHARMACEUTICALS, INC   |  ARSTASIS INC   |  CARDIAC DIMENSIONS INC   |  ARCELLX, INC.
MICHELLE 
 
GILSON 
EXECUTIVE OFFICER
ARCELLX, INC.
CHRISTOPHER 
 
HEERY 
EXECUTIVE OFFICER
ARCELLX, INC.
DAVID 
 
HILBERT 
EXECUTIVE OFFICER, DIRECTOR
ZYNGENIA, INC.   |  ARCELLX, INC.
HAN 
 
LEE 
EXECUTIVE OFFICER
NOTESFIRST, INC.   |  ARCELLX, INC.   |  ARBOR PACIFIC INC.   |  IMMPACT BIO USA INC.
DAVID 
 
LUBNER 
DIRECTOR
TETRAPHASE PHARMACEUTICALS INC   |  DYNE THERAPEUTICS, INC.   |  ARCELLX, INC.
KAVITA 
 
PATEL 
DIRECTOR
TESARO, INC.   |  RADIOLOGY PARTNERS HOLDINGS, LLC   |  PERSONAL GENOME DIAGNOSTICS INC.   |  ARCELLX, INC.
ROGER 
 
SAWHNEY 
DIRECTOR
ARCELLX, INC.   |  SIRPANT IMMUNOTHERAPEUTICS, INC.   |  BOBCATBIO, INC.   |  ACTUATE THERAPEUTICS, INC.
LANCE 
 
THIBAULT 
EXECUTIVE OFFICER
AADI BIOSCIENCE, INC.   |  ARCELLX, INC.
OLIVIA 
 
WARE 
DIRECTOR
ARCELLX, INC.
LEWIS 
T. 
WILLIAMS 
DIRECTOR
JUVARIS BIO THERAPEUTICS INC   |  FIVE PRIME THERAPEUTICS INC   |  EUREKA THERAPEUTICS, INC.   |  WALKING FISH THERAPEUTICS, INC.   |  ARCELLX, INC.
LEWIS T. 
RUSTY 
WILLIAMS 
DIRECTOR
ARCELLX, INC.
DEREK 
 
YOON 
DIRECTOR
CLEARSIDE BIOMEDICAL, INC.   |  TREFOIL THERAPEUTICS, INC.   |  ARCELLX, INC.   |  CARBON BIOSCIENCES, INC.   |  EVOLVEIMMUNE THERAPEUTICS HOLDING COMPANY, LLC
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2023-02-06
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2023-01-26 
2022-03-10
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2022-02-27 
2021-07-01
D/A
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2021-03-26 
2021-04-09
D
Link
BIOTECHNOLOGY 
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] 
DECLINE TO DISCLOSE 
Equity 
2021-03-26 
2019-10-15
D/A
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2019-08-09 
2019-08-22
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2019-08-09 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
SOLEBURY CAPITAL LLC
143299